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The objective of this study was to compare the cost-
effectiveness of four clinical policies (policies I to IV) in
the diagnosis of the presence or absence of coronary
artery disease. A model based on Bayes' theorem and
published clinical data was constructed to make these
comparisons. Effectiveness was defined as either the
number of patients with coronary disease diagnosed or
as the number of quality-adjusted life years extended by
therapy after the diagnosis of coronary disease.
The following conclusions arise strictly from analysis
of the model and may not necessarily be applicable to
all situations. 1) As prevalence of coronary disease in
the population increased, it caused a linear increase in
cost per patient tested, but a hyperbolic decrease in cost
per effect, that is, increased cost-effectiveness. Thus,
cost-effectiveness of all policies (I to IV) was poor in
populations with a prevalence of disease below10%, for
example, asymptomatic people with no risk factors. 2)
Analysis of the model also indicates that at prevalences
less than 80%, exercise thallium scintigraphy alone as
a first test (policy II) is a more cost-effective initial test
than is exercise electrocardiography alone as a first test
Both exercise thallium-20l myocardial perfusion imaging
(l,2) and cardiac blood pool imaging (l ,3) have been re-
ported to offer improved sensitivity and specificity over
exercise electrocardiography to diagnose coronary artery
disease . Other studies have demonstrated less improvement
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(policy I) or exercise electrocardiography first combined
with thallium imaging as a second test (policy IV). 3)
Exercise electrocardiography before thallium imaging
(policy IV) is more cost-effective than exercise electro-
cardiography alone (policy I) at prevalences less than
80%.4) Noninvasiveexercise testing before angiography
(policies I, II and IV) is more cost-effective than using
coronary angiography as the first and only test (policy
III) at prevalences less than 80%. 5) Above a threshold
value of prevalence of 80% (for example patients with
typical angina), proceeding to angiography as the first
test (policy III) was more cost-effective than initial non-
invasive exercise tests (policies I, II and IV).
One advantage of this quantitative model is that it
estimates a threshold value of prevalence (80%) at which
the rank order of policieschanges. The model also allows
substitution of different values for any variable as a way
of accounting for the uncertainty inherent in the data.
In conclusion, it is essential to consider the prevalence
of disease when selecting the most cost-effective clinical
approach to making a diagnosis.
in diagnostic accuracy by radionuclide imaging, and the
optimistic reports from large medical centers may not be
reproducible everywhere. These radionuclide tests certainly
remain imperfect and more expensive than exercise electro-
cardiography . The cost and false results of noninvasive stud-
ies. plus the relative safety of coronary angiography, have
led some physicians to recommend angiography rather than
noninvasive testing early in evaluation of patients with sus-
pected coronary disease (4- 6).
Assessment of the cost-effectiveness of health care is
exceedingly complex (7), particularly because of multiple
factors needed to define effectiveness (7- 9). Estimating cost-
effectiveness of management of coronary disease is partic-
ularly difficult because of the uncertainty concerning the
role of coronary artery bypass surgery (l0-13). The mag-
nitude of the problem of coronary disease and rising health
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care costs (1,14--16), however, require consideration of cost-
effectiveness of various clinical approaches to the diagnosis
of coronary disease despite problems inherent in the analysis.
The purpose of the present study was to devise a model
to test the following hypotheses: I) the prevalence of disease
in the population influences cost-effectiveness of any clin-
ical policy; 2) thallium-20l imaging is more cost-effective
than exercise electrocardiography as an initial screening test;
3) coronary angiography as an initial screening test is more
cost-effective than the less accurate noninvasive tests; and
4) sequential use of exercise electrocardiography followed
by thallium-201 imaging is more cost-effective than either
test alone as an initial screening test.
We used actual data from patients at Mount Sinai Medical
Center (17), the Framingham Study (18) and other epide-
miologic data (19,20) as well as the fees for tests allowed
by New York City Medicaid-Medicare. Furthermore, we
used previously published data for complication rates of
procedures (5,21-22) and coronary disease (5,11,12,23-35).
These real data were employed to develop a model to com-
pare the cost-effectiveness of four different specific clinical
policies to diagnose coronary disease . This limited objective
appears attainable and allows several important and realistic
comparisons of different clinical policies which are uniquely
determined by physicians.
Methods
A conceptual model was developed based on available
real data to estimate comparative cost-effectiveness of dif-
ferent clinical policies (policies 1 to IV) (Table I) for uti-
lization of noninvasive exercise tests . This model permits
varying the values of data that are very difficult to obtain,
such as the rates and costs of complications due to diagnostic
procedures or due to coronary disease in particular patient
groups .
Definitions of effectiveness of tests. The most difficult
problem in any assessment of cost-effectiveness is to define
effectiveness of health care (7-9) . For our purposes , we
defined effectiveness of the noninvasive tests in two ways,
the first being the ability to identify accurately a patient who
has coronary artery disease (8). This straightforward defi-
nition assumes that the goal of a test is to make a diagnosis;
it does not attempt to account for more controversial vari-
ables such as the risk, cost and benefit of medical or surgical
therapies .
Second , in an attempt to account for several of the com-
plex clinical variables that influence the effectiveness of
management of coronary disease, we also defined effec-
tiveness of tests for coronary disease in terms of the clinical
outcome for patients undergoing the tests, that is, an increase
in the number of quality-adjusted life years for a patient
over a 10 year follow-up period (Appendix 1) (36). We
multiplied the number of years of life extended by therapy
(over a 10 year follow-up period) by the adjusted quality
of life, expressed as a fraction of full health without symp-
toms. Although this value of quality-adjusted life years ad-
justed as a fraction of full quality of life per 10 years is
controversial , it does account for many important clinical
variables (36). It seems justifiable for our purpose because
it is used here only as a common denominator to facilitate
the comparison of effectiveness of different clinical policies.
Briefly, we assumed that the accurate diagnosis of coronary
disease increased the number of quality-adjusted life years
by 2 years over a 10 year follow-up period, based on a
synthesis of available data (12 ,21-35). We restricted this
variable to a 10 year follow-up period because the natural
history of patients treated with modem medical or surgical
therapies is not known beyond 10 years . If therapies have
a sustained long-term effect on the natural history of coro-
nary disease, then the outcome of therapy (number of qual-
ity-adjusted life years) would be more favorable than our
analysis indicates.
Calculation of cost-effectiveness (Appendix II). Cost-
effectiveness was illustrated as its inverse: cost per effect.
Specifically, we calculated total costs as direct costs (fees
for tests) times the number of patients tested (as decided by
physician's policy) plus the induced costs (the number of
patients tested times the costs of complications resulting
from test procedures or of coronary disease missed by false
negative test results) (8). Mortality from coronary disease,
Table 1. Clinical Policies (I to IV)* to Diagnose Coronary Disease
Clinical
Policy
I
II
III
IV
Exercise
Electrocardiography
1st
None
None
1st
Exercise
Thallium (TI-201 )
Imaging
None
lSI
None
2nd if ECG = positive
or nondiagnostic
Coronary
Angiography
2nd if ECG = positive or nondiagnostic
2nd if TI-20l = positive or nondiagnostic
1st
3rd if TI-20l = positive or nondiagnostic
*These policies represent proposals for testing, not our recommendations. ECG = electrocardiography; Tl-
201 = thaIlium-201 imaging.
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or from test procedures was not assigned any arbitrary dollar
value, but was considered separately or incorporated into
the calculation of quality-adjusted life years. We calculated
(cost-effectiveness) -I as cost (in dollars) per effect:
Direct costs + Induced costs
Effectiveness
where effectiveness is either a patient with coronary disease
diagnosed or an extension of the number of quality-adjusted
life years over a 10 year follow-up period. Calculation of
direct and induced costs is described briefly and with de-
tailed equations (Appendix II, using variables in Table 2).
The total direct costs, therefore, were calculated as the fee
for each test multiplied by the number of patients having
the test and summed for all tests. The fees for each test
were obtained from Medicare Part B Prevailing Charges for
All Covered Services, New York City, 1981, rather than
trying to estimate incremental costs. The fees for tests are
relatively fixed, but the number of patients who have a
particular test depends on the policy used by the physician
to decide which patients should have each test (Table 1).
Estimation of costs. The induced costs of exercise tests
are derived from the complications and mortality resulting
from each test, as well as from the complications and mor-
tality resulting from coronary disease that is inadequately
treated because of false negative test results. Costs of com-
plications are difficult to estimate, but we synthesized actual
data for this purpose. We assumed that the typical compli-
cation of each test or of coronary artery disease would be
nonfatal myocardial (or cerebral for angiography) infarction,
requiring 2 weeks in the hospital and 3 months away from
employment (5,22) at an average cost of $20,000 per com-
Table 2. Parameters Used in Calculation
plication. We adjusted the annual rate of nonfatal myo-
cardial infarction in patients with coronary disease (23) to
estimate the rate of infarction in the subgroup of patients
with symptoms not severe enough to require surgery and
with false negative exercise test results. Because we required
that the patient achieve 85% of age-predicted maximal heart
rate to interpret the test as negative, most patients with false
negative tests would have good exercise capacity and, there-
fore, a low risk of nonfatal myocardial infarction or death
(34,35). Furthermore, only patients with mild to moderate
symptoms are likely to avoid coronary angiography despite
negative exercise test results because patients with severe
symptoms are likely to be referred for angiography pending
surgery to relieve symptoms. There is evidence that patients
with mild to moderate symptoms have a relatively good
prognosis (35). Thus, we assumed a 15% rate of nonfatal
myocardial infarction over 10 years in patients with false
negative exercise test results.
We analyzed the sensitivity of the model to changes in
this variable by testing the effect of higher rates of com-
plications (50%) over 10 years in patients with coronary
disease missed because of false negative test results (Table
3). We assumed mortality rates for coronary artery disease
missed by false negative test results of 15% over 10 years,
after adjusting for the good exercise tolerance, mild to mod-
erate symptoms (34,35) and relative frequency of left main
or three vessel coronary artery disease in patients with false
negative exercise test results (17).
We used a modification of Bayes' theorem (37,38) to
calculate the number of patients having each test or expe-
riencing the complications (Appendix II). These calculations
were based on the sensitivities and specificities of each test
FE = fee for exercise electrocardiography = $175
FT = fee for exercise thallium-20l imaging = $385
FA = fee for coronary angiography = $2,825
C = cost of a complication = $20,000 (assumed to be myocardial infarction)
RE = rate of complications with exercise electrocardiography = 0.0005
RT = rate of complications with exercise thallium-201 imaging = 0.0005
RA = rate of complications with coronary angiography = 0.0075
RF = rate of complications per 10 years for patients with coronary disease but false negative exercise tests = 0.15
ME = mortality due to exercise electrocardiography = 0.00005
MT = mortality due to exercise thallium-201 imaging = 0.00005
MA = mortality due to coronary angiography = 0.0003
MF = mortality per 10 years for patients with coronary disease but false negative exercise tests = 0.15
SnE = sensitivity for exercise electrocardiography = 0.84 = true positive tests/all patients with coronary disease who have a diagnostic test
SPE = specificity for exercise electrocardiography = 0.62 = true negative tests/all patients with diagnostic tests who do not have coronary
disease
Ndxj, = rate of nondiagnostic exercise electrocardiography = 0.36 = patients with test result which is equivocal or not diagnostic/all patients
who had test
SnT = sensitivity of exercise thallium-201 imaging = 0.88
SPT = specificity of exercise thallium-201 imaging = 0.74
Ndx- = rate of nondiagnostic exercise thallium-201 imaging = 0.09
~QALY = quality-adjusted life years extended by therapy after making diagnosis of coronary disease (per 10 years of follow-up) = 2.0 years
Numbers represent fraction of patients unless indicated otherwise.
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Table 3. Sensitivity Analysis
A. Since each parameter is subject to error, we tested the effect on
calculations of varying parameters as follows from the standard
values in Table 2.
B. Low risk coronary angiography
C = $20,000 -+ $10,000
RA " 0.0075 -+ 0.0020
MA = 0.0003 -+ 0.0001
C. High risk if false negative, F( - ), exercise tests
C = $20,000 -+ $200,000
RF " 0.15 -+ 50
MF = 0.15 -+ 50
D. High impact of therapy to improve aQALY
Q = 2.0 -+ 5.0 (yr/IO yr)
E. Low cost coronary angiography
FA " $2,825 -+ $1,500
F. Low cost TI-201
FT = $385 -+ $175
situation at a particular institution and substituted in the
general equations (Appendix I and II).
Results
Effect of prevalence on costs. As the prevalence of
coronary artery disease increases in the population tested,
the cost and mortality rate over a 10 year follow-up period
also increase as linear functions (Fig. 1). As prevalence
increases, there are hyperbolic decreases in cost per patient
with coronary disease diagnosed and in cost per increased
number of quality-adjusted life years (Fig. 2), both indi-
cating increased cost-effectiveness. Thus, despite the in-
crease in absolute cost and mortality rate with increasing
B
A
m
Figure 1. Effects of disease prevalenceon cost (A) and mortality
rate (B) per patient tested for clinical policies I to IV. Prevalence
of coronary disease increases along the horizontalaxis. Dollar cost
(A) or mortality per patient tested over a 10 year follow-up period
(B) increases up the vertical axis. Note that cost and mortalityrate
perpatienttestedincreasewithprevalenceof diseasefor all policies
except policy III (angiography only). Cost is lowest at low prev-
alences for policy IV (electrocardiography before thallium), but
mortality rate is also highest for policy IV because of the high
false negative rate of sequential noninvasive test results. False
negative test results cause the cost of policy IV to become highest
at high disease prevalences, and false positive test results increase
the cost of policy I at the lowest disease prevalence.
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Abbreviations as in Table 2.
in our institution (17) (Table 2) and the assumed rates (0.0
to 1.0) of complications over the full range of prevalence
of coronary disease.
Clinical policies for employing diagnostic tests. Using
this model, we tested four different clinical policies for
employing diagnostic tests for coronary disease. The poli-
cies express several different and, necessarily, simplified
diagnostic approaches to coronary disease (Table 1). These
policies represent proposals to be tested, not our recom-
mendations. Patients are screened by exercise electrocardi-
ography (policy I) or exercise thallium-201 imaging (policy
II) and are referred for coronary angiography only if the
noninv asive test is positive or nondiagnostic. Although the
electrocardiogram would be monitored for arrhythmias dur-
ing exercise in policy II, the ST segment changes would
not be used to predict the presence or absence of coronary
artery disease by policy II. Policy III assumes that coronary
angiography is performed as the initial screening test. Policy
IV assumes that all patients have exercise electrocardiog-
raphy and that patients with positive or nondiagnostic results
are referred for exercise thallium imaging. Only those pa-
tients who also have positive or nondiagnostic thallium im-
aging are referred for coronary angiography.
Analysis ofdata. Since many assumptions are necessary
in any model of cost-effectiveness, we performed sensitivity
analysis of the model to these variables by repeating cal-
culations after making changes in the values of sensitivity,
specificity, fees, rates and costs of complications and mor-
tality (Table 3). In this way we attempted to deal with the
inherent inaccuracies of the available data, particularly to
determine whether these variables would influence merely
the quantitative cost-effectiveness or, more importantly, the
rank c-rder comparison of different clinical policies. All
variables used in the model could be varied to reflect the
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Prevalence vs. Cost-Effectiveness (t; QALYI
t; QALY=Increased Quality-Adjusted Life
Years Due to Dx and Rx of CAD
order of cost-effectiveness is the same at a 17% prevalence.
At 50% prevalence (atypical chest pain), policy II remains
the most cost-effective, but policy IV is least cost-effective
and differences among policies are less dramatic. At 90%
prevalence (typical angina) policy III (angiography only)
becomes most cost effective and policy IV is the least cost-
effective, Thus, the rank order of cost-effectiveness of pol-
icies I to IV changes as prevalence increases (Fig. 3).
Sensitivity analysis of variables inftuencing cost-ef-
fectiveness. Because accurate data are hard to obtain and
many assumptions are involved in these calculations, we
systematically changed several variables in the equations to
test their influence on cost-effectiveness (Table 2, Fig. 4
and 5). We analyzed the effects of changes in clinically
related variables; for example, low risk coronary angiog-
raphy involved a lower cost of complications as well as
lower rates of complications and death, When each policy
is examined over the range of prevalences (Fig. 4), cost-
effectiveness is improved most (lowest cost per quality-
adjusted life-years extended) if therapeutic results are better,
that is, if this value is extended from 2 to 5 years at full
health over a 10 year follow-up period (Fig. 5D) or if an-
giography is provided at a low cost (Fig. 5E). Reducing the
risk of angiography (Fig. 5B) or the cost of thallium imaging
(Fig. 5F) also improves cost-effectiveness. Cost-effective-
ness is reduced dramatically if the risk of complications and
death is high in patients whose coronary disease is missed
by false negative tests. Increasing the risk of a false negative
result has its greatest impact on policy IV (electrocardiog-
raphy before thallium imaging) because the probability of
a false negative result is highest.
Policy III (angiography only) became most cost-effective
under these conditions of increased risk (Fig. 5C) because
it had the fewest false negative results. Reducing the risk
of coronary angiography (Fig. 5B) caused a greater im-
provement in the cost-effectiveness of policy III (angiog-
raphy only) than did reducing the fee for angiography (Fig.
5E). In fact, low risk angiography made policy III even
more cost-effectivethan policy II (thallium) at all prevalences.
Discussion
Assessment of cost-effectiveness. Accurate assessment
of the cost-effectiveness of medical care is difficult, but in
view of the current spiraling cost of care, further analyses
are essential (7-9,14-17). Our study set out to achieve a
specifically limited objective, that is, to compare the relative
cost-effectiveness of four diagnostic approaches to the pa-
tient suspected of having coronary disease. We focused on
the aspect of cost-effectiveness-test selection, which is
uniquely decided by the physician and not currently by the
health care administrator or public policy maker. To com-
pare various clinical policies, a conceptual model was con-
structed based on available real data and Bayes' theorem
B
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a
prevalence of disease, cost-effectiveness improves at higher
prevalence. The most dramatic features of the hyperbolic
relation between prevalence and cost-effectiveness are the
very high cost (low cost-effectiveness) at low prevalences
and the dramatic differences among policies I to IV at lower
prevalences,
Comparison of clinical policies. Comparison of cost-
effectiveness of different clinical policies is clearest in par-
ticular patient examples selected to illustrate varied preva-
lences of disease (Fig. 3). In a population of 45 year old
men with no symptoms or risk factors to indicate a 3%
prevalence, policy II (thallium imaging only) is most cost-
effective, that is, lowest cost per effect, followed by policy
IV (electrocardiography before thallium) and policy I
(electrocardiography alone). Policy III (angiography only)
is the least cost-effective at the 3% prevalence. The rank
Prevalence vs. Cost per Patient with CAD Diagnosed
200,000..-------------------,
180,000
160,000
140,000
Cost per 120,000
CADDx 11 100,000
1$1 80,000
60,000 ~Im
40,000
20000 nz:~
a n
o 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
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Figure 2. Effects of disease prevalence on cost-effectiveness. As
the prevalence of coronary disease increases along the horizontal
axis, there are dramatic decreases in the dollar cost per patient
with coronary artery disease diagnosed (CAD Dx) (A), and the
cost per quality-adjusted life years (dQALY) extended (B), The
vertical axis is expressed as cost per effect, or (cost-effective-
ness)- I, The number of quality-adjusted life years is defined in
the text and Appendix I. Note that policy II (thallium imaging
only) is most cost-effective (lowest cost per CAD Dx or cost per
dQALY), and policy111 (angiography only) is least cost-effective
at low prevalences. CAD = coronary artery disease.
lACC Vol ~ . No.2
August 19~;":278-89
PATIERSON ET AL.
COSTS OF CORONARY DISEASE DIAGNOSIS
283
3% ~ Prevalence 17% ~ Prey 50% ~ Prey 90% ~ Prey(45 ylo Man with No 45 ylo if 45 ylo if 45 ylo cfSymptoms or Risk Factors) No Sym ptoms Atypical Typical
1!JO,OOO ~ 20,000 3 Risk Facto rs Chest Pain Ang ina
'-10,000 - 18,000 17,489
80,000
- 74,585 16,000~ ...-'-- ~ 14,283)( 10,000 - 65,057 14,000 13,6680
-
)(
00 00,000 I-
fJ'22C 0
12,000 1,271<t
u <t
Q; 'iO,OOO I- u 10,000
e. Q;
lii 40,000 l-
e. 8,000
0 lii
5 727 5 948 6.332u 0
lO,OOO I- u 6.000 ' 5.319 '
.10.000 I- 4.000
10,000 I- 2,000
0 0I II ill nr II ill nr II ill nr II ill nr
Figure S. Comparison of clinical policies I to IV in four specific
patient examples. The vertical axes show dollar cost per patient
with coronary artery disease diagnosed, and the horizontal axes
show policies I to IV for four different groups of 45 year old men
with a prevalence of coronarydisease increasing from left to right:
3, 17, 50 and 90% because of the clinical features cited (18,19).
Note that policy II (thallium imaging only) is most cost-effective
(lowest cost per CAD Dx) at disease prevalences of 3, 17 and
50%. Policy 11\ (angiography only) is leastcost-effective at disease
prevalences of 3 and 17%, but becomes most cost-effective when
disease prevalence increases to 90%. Abbreviations as in Fig-
ure 2.
(17,37 ,38) . Our conclusions arise strictly from analysis of
this model and shou ld not necessarily be construed as gen-
era l pol icy statements.
The most elusive aspect of assessing cost -effectiveness
has been an adeq uate definition of effectiveness so we used
two det initions of effectiveness. The se two definitions of
effectiveness yie lded concordant resul ts when comparing
the rank order of different clinical policies , and did not
require placing a dollar value on human life . The agreement
of resul ts using two definitions of effectiveness supports the
validity of the mode l. Our ana lysis addre ssed the use of
these tests for the specific purpose of determining whether
coro nary disease was present or absent. There are other
indications for these tests that are not addressed by the
present study, for example , predicting prognosis or func-
tional significance of a particular coronary lesion. Although
these indications are important, data eva luating the relia-
bility of the tests for these indications are quite limited .
Thus , we chose not to try to evaluate cost-effectiveness of
the test ; when used for these indications.
Our calculations of the number of quality-adj usted Iife-
years did not assess costs of medical versus surgical or no
therapy over 10 years. There is considerable controversy
concerning the cost-effectiveness of medical versus surgical
therapy for coronary disease (39-41) . Most important for
our purposes , these therapeutic variables would not influ-
ence the rank order of different clinical diagnostic pol icies ,
but rather would cause similar changes in the absolute cost
of all policies, Finally, we used a simplified approach to
calc ulating costs by using the test fees as the cost of the
test, rather than a more precise cost-accounting ana lysis of
all the factors that influence incremental costs (36) . Because
our analysis of the model depends on the rela tive rather than
the absolute cos t of different tes ts, our use of Medicaid fees
seems justifiable.
Effects of prevalence. Although both absolute dollar
cost s and mortality rates increase linearly with the preva-
lence of coronary artery disease , cost-effectiveness also in-
creases. The cost per effect decreased dramatically as the
prevalence of coronary disease in the population increased
above 10 to 15% because there are few patients with coro-
nary disease to benefit from therapy in populations with a
low prevalence of coro nary dise ase . Th is analysis illustrates
the fact that diagnostic testi ng for coronary disease in
asymptomatic low-risk populations is not generally cost-
effective . An important exception is illustrated by the 45
year old man with no symptoms, but with three risk factors
for coro nary disease (Fig . 3).
Increasing prevalence was associated with increased cost-
effectiveness for all clinical polic ies involving noninvasive
tests , because negative results of the noninvasive tests led
to decreased need for coronary angiography. At low prev-
alences, where most nega tive tes ts will be correct to excl ude
coronary artery disease (lower predictive error at lower prev-
alence), the clinical noninvasive test policies I, II and IV
are more cost-effective than policy III (angiography only) .
In contrast, at higher prevalences of coro nary disease
(above a threshold value of 80%), avoiding angiography
leads to missing many patients with coronary artery disease
and decreasing cost-effectiveness. Decreased cost-effec-
tivene ss at high prevalences results from the increasing per-
cent of patients with negative noninvasive tests results who
actually have coronary disease (higher predictive error at
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higher prevalence). Thus, at high prevalences (above 80%),
performing coronary angiography as the only test to diag-
nose coronary disease is the most cost-effective clinical
policy (policy III) according to this model.
Exercise electrocardiography versus thallium-20t im-
aging. Thallium-201 imaging is more cost-effective than
electrocardiography during exercise to diagnose coronary
artery disease in populations with low to high prevalences
of coronary disease (Fig. 2 and 3). It should be noted that
our values of sensitivity and specificity (17) were not sig-
nificantly higher for thallium-201 imaging than for exercise
electrocardiography. Thus, the advantage of thallium- 201
imaging in the present study seems to result from its lower
rate of nondiagnostic tests (p < 0.05), despite its two-fold
greater cost. Above a threshold value of 80% prevalence,
exercise electrocardiography becomes slightly more cost-
effective than thallium-201 because a higher percent of pos-
itive or nondiagnostic tests are correct (higher predictive
value) at a higher prevalence.
Sequential use of exercise electrocardiography before
thallium-201 imaging (Policy IV) is more cost-effective than
exercise electrocardiography alone in populations with a low
prevalence, because this combined test approach offers the
greatest chance of avoiding angiography. As prevalence
increases, cost-effectiveness of policy IV (sequential tests)
Figure 4. Sensitivity analysis of variables influencing cost-effec-
tiveness, comparing variations for each clinical policyplotted in-
dividually. Horizontal axes show prevalence of disease. Vertical
axes show dollar cost per increased AQALY. Policies I to IV are
plotted individually in panels I to IV, respectively. Curve A uses
the standard values of all variables and the variations (B to F) are
defined in Table 3. Abbreviations as in Figure 2.
decreases because there is a greater chance of false negative
results and subsequent deaths using two noninvasive tests
in this way (Fig. 1). Surprisingly, thallium-201 imaging
alone was more cost-effective than sequential tests over all
prevalences, probably because of the added costs of exercise
electrocardiography at low prevalences and the added chance
of false negative test results at high prevalences.
Sensitivity analysis of factors influencing cost-effec-
tiveness. A major advantage of our approach to evaluate
cost-effectiveness by a model is the ease with which one
can substitute any variable into any equation to test its im-
pact. This approach is one way to deal with the inherent
uncertainties of available data for costs, risks and clinical
outcomes. For example, the differences in cost-effectiveness
of policies I and II arise primarily from the differences in
sensitivity, specificity and the frequency of nondiagnostic
test results between exercise electrocardiography and thal-
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Figure 5. Sensitivity analysis of variables influencing cost-effec-
tiveness, comparing clinical policies I to IV in each plot for their
sensitivity to each variation in values of variables. Axes are same
as Figure 4. All policies are plotted in each panel (A to F). Labels
(A to F) for panels correspond to the variation in variables shown
in Table 3. Abbreviations as in Figure 2.
lium imaging. Furthermore, we found that decreasing the
risk or cost of thallium-20l or angiography improved the
cost-effectiveness of policy II or III, respectively (Table 3,
Fig. 4 and 5). The most dramatic changes in cost-effec-
tiveness, however, arose from changes in patient outcome
rather than from changes in costs. If the risk of death over
10 years after a false negative test increases from 15 to 50%,
there is a dramatic decrease in cost-effectiveness (Fig. 4C
and Fig. 5C). This decrease in cost-effectiveness is most
marked for policy IV (sequential tests), which permits the
most false negative results.
Thus, the physician who is concerned primarily with the
risk of missing coronary disease in a particular patient would
believe it is most cost-effective to recommend coronary
angiography (policy III) and not to recommend sequential
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noninvasive tests (policy IV). Similarly, if the physician
takes an optimistic view of the impact of surgical therapy
on the natural history of coronary disease, he or she might
assume an increase in the number of quality-adjusted life-
years from 2 to 5 years , and an increase in this value would
improve the cost-effectiveness of all tests. Thus , physicians
who have the most aggressive optim istic view of therapy
would be expected to consider all testing for coronary artery
disease, particularly angiography, to be more cost-effective
than would a physician with a more conservative therapeutic
view.
Clinical implications. Analysis of this model suggests
cost-effective approaches to the clinic al use of noninvasive
and invasive tests to make the diagnosis of coronary artery
disease . Most important, the physician should select a di-
agnostic approach based on the probability of coronary dis-
ease in the patient, estimated by symptoms and risk factors .
It is possible to estimate the probability of coronary disease
clinically before and after noninvasive testing (20,42,43).
Specifically , in patients with no symptoms or risk factors,
the probability of coronary disease is so low (18-21) that
it is difficult for even noninvasive testing to be cost-effec-
tive . This analysis may be important to physicians who
include exercise stress testing as part of an annual exami-
nation , regardless of the patient ' s history or risk factors.
Asymptomatic patients with riskfactors. In contrast, per-
sons with no symptoms but with some risk factors will have
a higher likelihood of coronary artery disease (19), which
makes testing much more cost-effective (Fig. 2). Exercise
thallium-20 I imaging appears to be more cost-effect ive than
exerci se electrocardiography because the greater cost is off-
set by the lower incidence of false positive and nondiagnos-
tic tests. In the event that exercise electrocardiography is
used in asymptomatic persons, it is more cost-effective to
perform exercise thallium imaging in patients with positive
or nondiagnostic exercise electrocardiography (policy IV) ,
rather than proceeding directly to coronary angiography (policy
I). Use of coronary angiography as an initial screening test
(policy III) is not justifiable in term s of cost-effectiveness
in asymptomatic persons, even those with multiple risk factors.
Atypical chest pain. In patients with chest pain symp-
toms not typical of angina pectori s, there is an intermediate
probability of coronary artery disease. This higher pretest
likelihood of disease makes all testing approaches more cost-
effective and reduce s the dramatic cost differences among
different clinical approaches to the use of diagnostic tests.
Thallium-201 imaging remains the most cost-effective initial
screening test , but the initial use of coronary angiography
becomes quite competitive in terms of cost-effectiveness.
Coronary spasm. Our analysis did not cons ider the ad-
ditional benefits of testing for coronary spasm in patient s
with atypical chest pain. Since these provocative tests are
performed with greatest safety and accuracy during cardiac
catheterization, coronary angiography might be most useful
in patients who are suspected of having coronary spasm. In
addition, the model did not account for the cost sav ings in
a small percent of patient s with disabling symptoms of chest
pain who are found to have normal coro nary angiograms.
Thi s small but important group may avoid repeated hospi-
talizations after a normal coronary angiogram (44) . The
demon stration of coronary spasm in many of these patient s
in recent years , howe ver, indicates that their best manage-
ment may require hospitalization to avoid acute myocardial
infarction in some patients (45) .
Because of these mult iple uncert aintie s about manage-
ment , we did not attempt any calculation of cost saving s
related to excluding coronary disease. Sequential use of
exercise electrocardiography and thallium-20l imaging is
slightly less cost-effective than angiography in patients with
atypical chest pain because of the increased incidence of
false negative results using two noninvasive tests. Note that
patient s with false negati ve results who avoid angiography
by this policy would include patients with positive or non-
diagnostic exercise electrocardiograph y but negati ve thal-
lium-20 I imaging. In contrast, we previously indicated that
it would be more cost-effective to avoid angiography in
patients with atypical chest pain if both exercise electro-
cardiography and thallium-201 imaging are negative at a
heart rate greater than 85% of the age-predicted maximum
(17).
Typical angina pectoris . In patients with typical angina
pectoris, the most cost-effective approach to confirm the
diagnosis of coronary artery disease is to perform coronary
angiography as the initial test. In addition, angio graphy
provides the most reliable prognostic information for coro-
nary disease and is the essent ial test before considering
surgery (4). Since functional aerobic capacity for exercise
may add useful prognostic information, noninvasive exer-
cise tests might be indicated after angiography in some
patients to help clarify which patients need surgery (21,34,35).
To incorporate these indicati ons for tests into the model
would require many addit ional assumptions and use of data
that have not been widel y tested . For example , available
studies (34,35) using stress tests to predict prognosis are
based on a very small number of deaths. Furthermore , the
use of stress tests to evaluate the hemodynamic significance
of an anatomic lesion observed angiographically remains
intuitively attracti ve but not validated . Thus , we sacrificed
testing some potentially important and clinically relevant
hypotheses in the interest of making the conclusions more
reliable. This approach to modeling cost-effectiveness of
various health care policies may have useful applications in
clinical problems outside card iology.
We are grateful for the computer programming assistance of Douglas
McGuire and for the expert preparation of the manuscript by June Moon .
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Figure 6 represents the difference in dQALY over a 10
year follow-up period between patients in whom coronary
arterydisease was diagnosedaccurately("CAD Dx," upper
panel) versus the same patients if they had not had angi-
ography to confirm coronary artery disease ("No Dx," lower
panel). The average length of life over a 10 year follow-up
period is shown, as is the subjective quality of life, ex-
pressed as a fraction of life at full health (Qzyr), Making
the diagnosis of coronary artery disease leads to a higher
dQALY: 6.07 - 4.05 = 2.02 years (Fig. 6, upper panel
minus lower panel). This calculation is based on a synthesis
of availabledata. First, 40% of patientswithcoronaryartery
disease diagnosed would have coronary bypass surgery for
left main or three vessel coronary artery disease or intract-
able symptoms (upper panel) (11). These surgical patients
wouldhave an 80% 10year survival(upperpanel)compared
with a 33% 10 year survival of the same patients treated
without surgery ("No Surgery," lower panel) (11,25-29).
Patientswho died after surgeryhad a 4 year averagelifespan
after surgery and a lower quality of life (Q/yr = 0.6) than
did surgical survivors(Q/yr = 0.9). The number of quality-
adjustedlife years for surgical patients is calculated by mul-
tiplying the fraction of patients having surgery (0.4) by the
fraction of patients surviving 10 years (0.8) == 0.32 (upper
panel). This figure is multiplied by the number of years
survived (10) and the Q/yr (0.9) to yield 2.88 years. Similar
computations for patients who died after surgery yield 0.19
years, which is added to yield dQALY of 3.07 years for
surgical patients.
Sixty percent ofpatients were treated medically. and half
of these patients lived at 10 years after angiography (upper
panel). Multiplying the fraction of patients alive at 10 years
(0.3) times the average length of life after angiography (10
years for survivors versus 5 years for those who died) times
Q/yr (0.7 in survivorsversus 0.6 in those who died) yielded
dQALY values of 2.1 years for survivors versus 0.9 years
for those who died. The overall dQALY for patients treated
medically after angiography (3.0 years, upper panel) is 10%
higher than that for the same group of patients if they had
not had angiography to prove the diagnosis of coronary
artery disease (2.73 years, lower panel). This slight im-
provement in dQALY by angiography is assumed to result
from a small improvement in Q/yr due to more vigorous
therapy of patients known to have coronary artery disease.
Sensitivity analysis of the model indicated no change in
the rank order of cost-effectiveness for different policies
when the improvement in dQALY was varied from 0.5 to
5.0 years. Thus, the particular value of improved dQALY
due to coronary artery disease diagnosis changed the ab-
solute dollar cost, but not the relative ranking of different
clinical policies. This value of improved dQALY due to
diagnosis of coronary artery disease estimated in Figure 6
was then applied to each individual clinical policy (I to IV)
0.08
x 4 Yrs
x 0.6 Q/Y,
~ 0.19
I
0.27
x 4 Yrs
x 0.5 Q/Y,
~ 0.54
I
0.4
3.07
1.33
I
0.32
x 10 Yrs
x 0.9 Q/Y,
= 2.88
I
0.13
x 10 Yrs
x 0.6 Q/Y,
= 0.79
I
ITk]OALY
~OALY
0.3
x 5 Yrs
x ~Q/Y,
= 0.9
I
0.31
x 5 Yrs
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= 0.86
I
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i-Medical
o~
~]
0.3
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x 0.7 Q. Yr
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Figure6. Calculation of the improvement in LlQALYfor patients
with an accurate diagnosis of coronary artery disease (upper dia-
gram) or without an accurate diagnosis of coronary artery disease
(lower diagram). Decimals refer to fraction of all patients (1.0)
entering each subgroup, that is, medical versus surgical therapy
and alive versus dead after IO years. The fraction of patients is
recomputed foreach subgroup and multiplied byaverage life span
(over IO year follow-up period) and theaverage subjective quality
of life shown by thedecimal fraction of life at full health with no
symptoms (1.0). The LlQALYvalues foreach group are then added
to show that a positive diagnosis leads to surgery in 0.4 of the
patients and a better LlQALY (6.07 - 4.05). Abbreviations as in
Figure =.
Appendix I
Calculation of Improvement in ~QALY for Patients
With and Without an Accurate Diagnosis of
Coronary Artery Disease (Fig. 6)
The particular value of the increase in quality-adjusted
life year, (dQALY) is obviouslycontroversial and based on
conflicting data. The calculation is used in the present study
only as a common denominator to modify the benefit of
diagnosing coronary artery disease by each of the four clin-
ical policies. Rather than to compute the absolute cost of
each individual policy, the goal of the present study was to
comparecost-effectiveness of four differentclinicalpolicies
to diagnose coronary artery disease.
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using the equations in Appendix II. We calculated net qual-
ity-adjusted life-years for each policy and this reflects not
only the effect of diagnosis (8QALY) but also the effects
of complications and mortality rates due to tests and coro-
nary artery disease missed by false negative tests.
Appendix II
Equations to Estimate Cost-Effectiveness for Each
Clinical Policy
Table 2 shows variables used in calculations.
Policy I: exercise electrocardiography (EX ECG) only in
all patients; coronary angiography (angio) performed only
if Ex ECG = positive (+ ) or nondiagnostic (Non-Dx).
Costs "" NdFE'RE'C) + NA'(FA + RA'C)
+ NdRdRF'C] and
mortalities « NE·ME + NA'MA + NF'Mp,
where P "" prevalence of coronary artery disease (CAD) in
population;
NE = number of patients having initial test; Ex ECG. =
1.0;
NA = number of patients having angiography because of
(+) or Non-Dx Ex ECG = Ndl- Ndxg) . P'SnE
+ (I-P)-(I-SpE) + NE· NdxE;
NF = number of patients with falsenegative (- )ExECG
who do not have angio for CAD Dx "" NE '
(I - Ndx-):P'(I - SnE);
CAD Dx = patients with CAD diagnosed correctly by the pol-
icy (first definition of " effectiveness" of policy)
Ndl-NdxE)'P'SnE + NE,P,NdxE;
AQALY = quality-adjustedlife yearsextended bytherapy due
to the diagnosis of CAD by the policy = 2 years
(Appendix 1) (seconddefinition of' 'effectiveness"
of policy).
Net QALY = net quality-adjusted life years extended
by therapy for a particular policy, taking into account not
only the favorable effect of CAD diagnosis (AQALY), but
also the deaths and complications of tests and CAD missed
that result from application of the particular policy.
Net QALY = (CAD Dx)- (~ALY) - 10 .
(NE'ME' + NA,MA) + 5, (NF'Mf ) +
10(0.1 ) (NE,RE + NA,RA + NF'Rf ) .
where deaths due to diagnostic tests subtract 10 years and
deaths due to coronary artery disease missed by false neg-
ative tests subtract an average of 5 years, Complications
due to tests or coronary artery disease missed reduce the
quality of life per year (Q/yr) by 1,110 per year.
Policy II: exercise thallium-201 imaging (Ex Tl-201)
only; angio performed only if Tl-20l = positive or Non-
Dx (equations are identical to policy I, substituting values
for fees, test sensitivity, specificity and rates of nondiagnos-
tic tests of Tl-201 for Ex ECG).
Policy III: coronary angiography is the first and only test
to diagnose coronary artery disease,
Costs = NA,(FA + RA, C),
mortality = NA,MA,
where NA = NE from policy I = 1.0;
NF = 0;
CAD Dx = NA 'P;
Net QALY = (NA,<1QALY'P - [IO'NA'MA + NA·RA).
Policy IV: exercise ECG in all patients; TI -201 per-
formed only if Ex ECG = positive or Non-Dx; angio per-
formed only if Tl-201 = positive or Non-Dx.
Costs = NE'(FE + RE'C) + NT'(FT + RT'C)
+ NA,(FA, + RA'C) + NF·RF·C,
Mortality = NE'ME + NT'MT + NA,MA+ NF'MF,
where NE = 1.0 = all patients having Ex ECG;
NT = patients having Tl-201 because of (+) or Non-
Dx Ex ECG = NE' (1- NdxE)'P'SnE + Ndl
- NdxE) ' (I - P) , (I- SPE) + NE'NdxE;
NA = patients having angiography because of ( +) or
Non-Dx TI-201 = Ndl -NdxT)'P'SnT + NT'
(1 - NdxT)-(I - P)'(I- Sp-) + NT,NdxT;
NF = number of patients with false negative Ex ECG
or TI-201, or both. whodo not have angiography
for CAD Dx
Ndl -NdxE)'P' (I-SnE) +
NT'(1-NdxTH'(I -SnT);
CADDx = patients with coronary artery disease diagnosed
correctly by the policy
NT'(l- NdxT)'SnT'P + NT,NdxT'P;
8QALY = quality-adjusted life years extended by ther-
apy due to diagnosis of CAD by the policy = 2 years,
Net QALY for this particular policy
= (CAD Dx)'(AQALY) - IO' (NE'ME + NT'MT + NA,MA )
+ 5,(NF,MF) + 10(0.1) (NE'RE + NT'RT + NA'RA) +
NF·RF .
We did not attempt to compute the 10year cost of medical
versus surgical therapies for coronary artery disease with
versus without a positive diagnosis, These highly contro-
versial values (39-4 1) would influence each patient diag-
nosed with coronary artery disease similarly and, thus, would
have little effect on the comparison of different clinical
policies.
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